Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 8/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650121 | 0.85 | STAT3 (0.51) | STAT3MEP1BGCGRPTGESLPAR1 | |
| Hydrochloric Acid SCHEMBL4929857 | 0.84 | STAT3 (0.50) | STAT3MEP1BGCGRPTGESLPAR1 | |
| SCHEMBL4936910 | 0.80 | SMN1; SMN2 (0.52) | STAT3FAAHALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4938902 | 0.77 | FFAR4 (0.51) | STAT3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13009721 | 0.77 | BCHE (0.38) | STAT3MAPT | |
| SCHEMBL21656950 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21656481 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2889790 | 0.75 | FFAR4 (0.41) | STAT3MAPTGCGR | |
| SCHEMBL13009762 | 0.74 | FFAR1 (0.44) | — | |
| SCHEMBL25752441 | 0.74 | STAT3 (0.76) | STAT3ALDH1A1MAPTSMN1; SMN2GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
| US-6939990-B2 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | SDHA, GOT2, MDH2 | STAT3 3798/4885MEP1B 1653/4885FAAH 1333/4885 |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | DDC, DAO, AADAT | STAT3 416/4885MEP1B 2448/4885FAAH 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.